The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the Midwest CEPAC process, and Find out how topics are selected.

Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the Midwest CEPAC must meet ICER’s criteria for Conflict of Interest.

The box below provides information on the topic of the next meeting of the Midwest CEPAC. For more information about past and other upcoming meetings, see the box to the right.


Next Meeting

September 13, 2018 9am- 5pm CT

Chicago Marriott at Medical District/UIC

625 S Ashland Ave

Chicago, IL 60607

Amyloidosis

The Midwest CEPAC will deliberate and vote on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council will also review a report on therapies for prostate cancer during this meeting.

Register

Amyloidosis

ICER will review new therapies for the treatment of hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone.

The review is expected to include inotersen (Ionis Pharmaceuticals, Inc.), an antisense oligonucleotide that interferes with transthyretin production in the liver, and patisiran (Alnylam Pharmaceuticals), which inhibits transthyretin through an RNA interference pathway. Approvals are expected in October and August of 2018, respectively.

View materials


Meetings

November 29, 2018 Asthma
September 13, 2018 Amyloidosis
September 13, 2018 Prostate Cancer
May 17, 2018 Cystic Fibrosis
January 25, 2018 Voretigene Neparvovec
September 14, 2017 Ovarian Cancer
May 25, 2017 Atopic Dermatitis
May 26, 2016 Multiple Myeloma
See more